AI-Enhanced Blood Test for Early Alzheimer’s Detection Now Available in India

An AI-integrated blood biomarker test for the early detection of Alzheimer’s disease has been launched in India, offering clinicians a less invasive and more accessible tool to identify Alzheimer’s pathology before significant cognitive decline occurs. The test, part of a broader diagnostic pathway supported by PET and MRI imaging, has received approvals from US and Indian regulatory authorities, marking a significant shift in dementia diagnostics in the country.

 

Regulatory and Clinical Breakthrough

New Diagnostic Standard for Alzheimer’s

The pTAU217/β-amyloid1-42 plasma ratio test, integrated with artificial intelligence analysis, is US FDA- and Central Drugs Standard Control Organisation-approved, aligning Indian clinical practice with evolving global standards for Alzheimer’s diagnostics. Unlike traditional cerebrospinal fluid testing, this blood-based approach provides critical biomarker insights with minimal invasiveness, improving patient acceptance and clinical uptake.

 

Healthcare Impact and Access Expansion

Transforming Dementia Care in India

By coupling the blood test with structured PET and MRI imaging pathways, the new diagnostic model aims to shift from symptom-led assessments to biology-first detection. This early identification capability enables timely intervention planning and supports families and care teams in managing the growing burden of dementia in India, where millions are affected.